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The expression of the cell cycle inhibitor p21 is increased in response to various stimuli and stress
signals through p53-dependent and independent pathways. We demonstrate in this study that fork-
head box A1/2 (FOXA1/2) is a crucial transcription factor in the activation of p21 transcription via
direct binding to the p21 promoter in p53-null H1299 lung carcinoma cells. In addition, histone
deacetylase inhibitor trichostatin A (TSA)-mediated upregulation of p21 expression was repressed
by knockdown of FOXA1/2 in H1299 cells. Consequently, these results suggest that FOXA1/2 is
required for p53-independent p21 expression.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The cyclin-dependent kinase (CDK) inhibitor p21 is a cell cycle
regulator, which acts through its binding to the cyclin/cyclin-
dependent kinase complex. It inhibits cell proliferation both
in vivo and in vitro, and introduction of p21 into normal or cancer
cells results in G1 phase arrest [1,2]. Regulation of p21 expression
is mainly controlled at the transcriptional level by the transcription
factor p53. However, various transcription factors target different
sites of the p21 promoter to regulate p21 expression by a p53-
independent pathway, such as p53-responsive element (p53-RE),
speciﬁcity protein 1 (SP1)-RE, and E-boxes [3,4]. For example,
SP1 upregulates p21 expression in p53-null Caco-2 cells derived
from human colon carcinoma [5]. In addition, transcription factors
such as ataxia telangiectasia-mutated (ATM), c-Myc, breast cancer
1, early onset (BRCA1), and Kruppel-like factor 6 (KLF6) canregulate the cell cycle and suppress cell growth by activating p21
transcription even in the absence of p53 [6–9]. Checkpoint kinase
2 (Chk2)-dependent induction of p21 transcription occurs in
p53-defective breast carcinoma SK-BR-3 and HaCaT cells [10]. In
this regard, ﬁnding of the transcriptional mechanism of p21 in a
p53-independent pathway is noteworthy to approach the p53-
deﬁcient cancer therapy using functionally combinatorial actions
of transcription factors.
The transcription factor forkhead box A2 (FOXA2) is a member
of the forkhead box (FOX) gene family with a common ‘‘winged
helix domain’’ for DNA binding [11]. In developmental stages it
plays an essential role in the formation of the primitive streak
and endoderm, and maintains homeostasis in the liver, pancreas,
intestine, and lung after birth [12,13]. FOXA2 is highly expressed
in type II pneumocytes and regulates the transcription of
lung-speciﬁc genes such as Titf1, Sftpb, and Scgblal, which play
important roles in lung morphogenesis and homeostasis [14–17].
On the other hand, downregulation of FOXA2 expression has been
reported in a large proportion of lung cancer cell lines [18,19],
which implies that FOXA2 is a candidate for the suppression of
lung cancer. For example, induction of FOXA2 expression in the
NCI-H358 non-small cell lung cancer cell line results in prolifera-
tion arrest and apoptosis [18]. In addition, FOXA2 suppresses
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transition and invasion in human lung cancer cells [20]. However,
the tumor suppressive mechanism of FOXA2 by the regulation of
target genes in p53-independent lung carcinoma cells is not fully
understood. Among the Foxa family including FOXA1, FOXA2,
and FOXA3, only FOXA1 and FOXA2 are expressed in the lung
and the temporal-spatial expression patterns of FOXA1 and FOXA2
are similar [13,21,22]. In this study, we investigated forkhead box
A1/2 (FOXA1/2) as a new transcription factor for the upregulation
of p21 expression by binding to its promoter in p53-null human
lung cancer H1299 cells.
2. Materials and methods
2.1. Cell culture and transfection
H1299 cells were obtained from the American Type Culture Col-
lection (ATCC; Manassas, VA, USA) and maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (Invitrogen,
Carlsbad, CA, USA) and penicillin–streptomycin (50 units/ml).
Transient transfection was performed using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) with different plasmid DNA accord-
ing to the manufacturer’s instructions.
2.2. Plasmid constructs
Details for plasmid constructions are described in the Supple-
mentary material.
2.3. Western blotting
Western blot analysis was performed as described previously
[23]. The monoclonal antibody against green ﬂuorescent protein
(GFP; 11814460001) was purchased from Roche Diagnostics (Indi-
anapolis, IN, USA) and that against acetyl-a-tubulin (T-6793) was
obtained from Sigma Aldrich (St. Louis, MO, USA) and that against
FOXA1 was obtained from active motif (#39837, Carlsbad, CA,
USA). Polyclonal antibodies against b-tubulin (sc-9104), p21
(sc-397), and SP1 (sc-59) were purchased from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA) and that against FOXA2 (#3143)
was obtained from Cell Signaling Technology (Danvers, MA, USA).
Western blotting was visualized by chemiluminescence using an
ECL system (Santa Cruz Biotechnology Inc.).
2.4. RNA extraction and quantitative real-time polymerase chain
reaction (qRT-PCR)
Total RNA extraction and qRT-PCR was performed as described
previously [24]. The expression levels of human p21 and 18SrRNA
in H1299 cells were determined by qRT-PCR using the following
forward and reverse primers: p21 (50-TGTGATGCTAGGAACATGAG
CAA-30 and 50-GTGGAAAGCCCAAGCCTGAA-30, respectively) and
18SrRNA (50-GATTA AGCCATGCATGTCTA-30 and 50-GTCGGGCGCCG
GCGGCTTTG-30, respectively).
2.5. Electrophoretic mobility shift assay
Oligonucleotide labeling and electrophoretic mobility shift
assays were conducted as described by Hellman et al. [25]. Details
are described in the Supplementary material.
2.6. Luciferase assay
H1299 cells were cultured in 60-mm dishes and transfected
using Lipofectamine 2000 with the indicated vectors containing
the luciferase reporter constructs (0.1 lg) and pCMV-b-galactosi-
dase. The cells were lysed in reporter lysis buffer 48 h after transfec-tion (Promega, Madison, WI, USA). Cell lysates were then analyzed
with the luciferase reporter assay system using a GloMax lumino-
meter (Promega). Luciferase activities were normalized to the b-
galactosidase activity of the cotransfected vector. All transfection
experiments were repeated independently at least three times.
2.7. Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was conducted following the protocol provided by
Upstate Biotechnology (Lake Placid, NY, USA), and as described
previously [24]. H1299 cells were sonicated to shear chromatin
to 500–1000 bp fragments. For immunoprecipitation, 2 lg of
anti-FOXA1/2 antibody was incubated with the cell lysates
overnight at 4 C with rotation. Lysates were immunoprecipitated
with IgG as a control. Precipitated DNA was analyzed by quantita-
tive real-time PCR using p21 promoter-speciﬁc primers, as
indicated in Supplementary material Table S1.
2.8. Statistical analysis
Analysis of variance was conducted to determine statistical sig-
niﬁcance, and signiﬁcance between two different experimental
groups was determined with Tukey’s post hoc comparison test
using SPSS, version 19 (SPPS Inc.; Chicago, IL, USA). All experiments
were repeated at least three times. The levels were considered very
signiﬁcant at P < 0.01 (⁄⁄), obviously signiﬁcant at P < 0.001 (⁄⁄⁄).
3. Results
3.1. The transcription factor FOXA1/2 induces the expression
of endogenous p21
Although many anti-cancer drugs have been designed to target
the p53 protein, their therapeutic effect is limited in cancer
patients who have absence of p53 expression or non-functional
p53 [26–28]. To overcome this limitation, we have made an effort
to ﬁnd an alternative transcription factor and have previously
reported that the p53 family member p73b regulates p21 tran-
scription by interacting with p300 [29]. In order to identify novel
transcription factors that might bind to the p21 promoter to regu-
late its expression in p53-null human H1299 cells, we used Search-
ing Transcription Factor Binding Sites (TFSEARCH) software
(version 1.3). As shown in Fig. 1A, transcription factors including
SP1, proto-oncogene c-Myc, sex determining region Y (SRY)-box
5 (SOX5), GATA binding protein 3 (GATA3), and activator protein
1 (AP-1), SRY were identiﬁed as putative binding factors for p21
promoter regions. Interestingly, we found that the transcription
factor FOXA1/2 binding sites had the higher binding scores than
the other transcription factors. More speciﬁcally, our analysis
found that there were two putative responsible elements of
FOXA1/2 at position 596 to 585 and 451 to 440 from the
transcription start site of the p21 promoter.
To determine whether FOXA1/2 is a transcriptional regulator of
p21, we analyzed the expression of endogenous p21 in p53-null
H1299 cells, which were transfected with a GFP-fused FOXA1/2
expression plasmid. Transiently overexpressed FOXA1/2 induced
about 3-fold increase in p21 mRNA and its protein (Fig. 1B). Taken
together, these results demonstrate that the expression of p21 is
positively regulated by FOXA1/2.
3.2. FOXA2 upregulates p21 transcription via direct binding to the p21
promoter
To examine whether FOXA2 regulates p21 transcriptional
activation via its responsible elements, we performed luciferase
reporter assays using wild-type or truncated fragments of p21
Fig. 1. The human p21 promoter contains putative FOXA1/2-binding motifs and endogenous p21 expression is induced by transcription factor FOXA1/2. (A) The human p21
gene (NCBI gene ID 1026) promoter was analyzed using a motif searching program to identify the binding sites for transcription factors. Consensus binding sites are
underlined and the FOXA1/2 binding site is in bold text and underlined. (B) After H1299 cells were transfected with a GFP empty vector or a GFP-FOXA1 vector, and/or a GFP-
FOXA2 vector, expression of p21 mRNA (normalized to 18S rRNA) was examined by qRT-PCR and the expression of p21 protein (normalized to b-tubulin) was examined by
Western blotting. Data are presented as the means ± S.E.M. from three independent experiments. (⁄⁄P < 0.01).
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which the following region had been deleted: FOXA1/2 responsible
element 1 (FRE1) containing putative binding site at 596 to 585
of p21 promoter, FOXA1/2 responsible element 2 (FRE2) containing
putative binding site at 451 to 440 of p21 promoter and FRE
deleted region (DFRE) without FRE1 and FRE2. The wild-type of
p21 promoter (WT-Luc) encompassing nucleotides 992 to 196
was signiﬁcantly induced about 11.7-fold increase of the luciferase
reporter activity under FOXA2 overexpressed condition compared
to the mock-Luc empty vector (Fig. 2A, right panel). While the
reporter activity of p21 FRE2-luc maintained about 9-fold increase,Fig. 2. FOXA2 regulates p21 transcription via direct binding to the responsible elemen
constructs (left panel). H1299 cells were cotransfected with each of the constructs and
eight hours after transfection, luciferase activity was measured. All data were normaliz
luciferase units, which are normalized to control levels. Data are the means ± S.E.M. from
GST-FOXA2 DBD (lane 4–8) proteins were used for an electrophoretic mobility shift assay
used as the hot probe. (C) The p21 promoter containing a FRE2 was labeled with 32P as t
Anti-GST antibody and rabbit IgG was used for immunoprecipitation (SS, supershifted ba
(lane 7).the promoter activity of p21 FRE1-luc shows about 4-fold increase
as similar as that of p21 DFRE-construct indicating that 4-fold
increase seems to be the basal promoter activity of FRE-deﬁcient
p21 promoter construct. These results indicate that the FRE2 at
positions 451 to 440 is mainly responsible for the FOXA2-med-
iated transcriptional activation of p21.
To examine whether FOXA2 directly bound to its responsible
element within p21 promoter, we conducted an electrophoretic
mobility shift assay (EMSA) using a glutathione S-transferase
(GST)-fused recombinant protein including FOXA2 DNA binding
domain (DBD). As shown in Fig. 2B, incubation of the FRE2 hott in p21 promoter region. (A) Schematic diagram showing p21 promoter deletion
pCMV-b-galactosidase together with a plasmid encoding GFP-FOXA2 cDNA. Forty-
ed to b-galactosidase activity. Data are expressed as the fold increase over relative
three independent experiments. (⁄⁄⁄P < 0.001). (B, C) Puriﬁed GST (lane 2 and 3) or
(EMSA). (B) The p21 promoter containing either FRE1 or FRE2 labeled with 32P was
he hot probe and unlabeled p21 oligonucleotide was used as a competitor (lane 8).
nd; S, shifted band; FP, free probes). Rabbit IgG were included as negative controls
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complexes in a GST-FOXA2 DBD dose-dependent manner (right
panel, lanes 4 and 5), whereas FRE1 hot probe produced weakly
shifted DNA band by FOXA2 DBD (left panel, lane 4 and 5), indicat-
ing that FOXA2 binds to FRE2 preferentially. Moreover, the pres-
ence of the GST-FOXA2 DBD in the protein-p21 FRE2 probe
complex was veriﬁed using an antibody against GST, which super-
shifted a portion of the FOXA2 DBD-p21 FRE2 probe complex
(Fig. 2C; lane 6, arrow SS). In contrast, the IgG negative control
did not prevent the migration of the FOXA2 DBD-p21 FRE2 probe
complex (Fig. 2C; lane 7). Shifted band by complex of the p21
FRE2 probe and GST-FOXA2 DBD was signiﬁcantly reduced when
a cold p21 FRE2 probe was added as a competitor (Fig. 2C; lane
8). All together, these results suggest that FOXA2 induces p21 pro-
moter activity by direct binding to the FRE2 of p21 promoter
in vitro.
3.3. p21 transactivation induced by trichostatin A (TSA) is regulated
by FOXA1/2
We next investigated the effect of several inducers, such as
doxycycline, doxorubicin, TSA, etoposide, cisplatin, and epigalloca-
techin gallate (EGCG) on endogenous FOXA2 expression in H1299
cells. Although FOXA2 is constitutively expressed at low levels in
H1299 cells [20], protein expression of FOXA2 was upregulated
by TSA treatment but none of the other inducers (data not shown).
In addition to FOXA2, The level of FOXA1 protein was also signiﬁ-
cantly increased by treatment with 1 lM TSA from 1 to 12 h in a
time-dependent manner (Fig. 3A). Since it has been previously
reported that TSA upregulates p21 transcription [30], we next
examined the functional effect of FOXA1/2 on TSA-induced p21
expression in H1299 cells. When we blocked TSA-induced FOXA1
and FOXA2 expression using their speciﬁc siRNAs that have no
cross-ablation each other, knockdown of FOXA1/2 inhibited the
levels of TSA-induced p21 expression to 50–80% of control level,
respectively (Fig. 3B; right panel, lane 3 and 4). Silencing of
FOXA1/2 together reduced p21 expression to 80% of control level,
as knockdown of FOXA2 decreased level (Fig. 3B; lane 5). These
results demonstrate that the expression of p21 induced by TSA is
speciﬁcally regulated by FOXA1/2 in H1299 cells.
To examine whether FOXA1/2 binds to the p21 promoter in vivo
during TSA treatment, we performed a ChIP assay with TSA-treated
H1299 cells using FOXA1/2 antibody. As shown in Fig 3C, the region
of p21 promoter containing FRE1 and FRE2 was precipitated by
FOXA1/2, whereas normal rabbit IgG used as a negative control
did not immunoprecipitate the p21 promoter. In same conditions,
moreover, we showed FOXA2 recruitment to PDX1 promoter which
is known as the FOXA2 target gene [31], indicating that FOXA1/2
directly binds to the p21 promoter in response to TSA in H1299 cells.
To further conﬁrm the direct binding of FOXA2 to the FRE2
within p21 promoter in vivo, we performed a ChIP analysis using
the distal and proximal region from transcription start site, FRE1
and FRE2 site of p21 promoter in TSA-treated H1299 cells. As
shown in Fig. 3D, precipitation of p21 FRE2 fragment by FOXA2
was signiﬁcantly increased in TSA-treated H1299 cells, whereas
p21 FRE1 promoter was not precipitated by FOXA2. In addition,
p21 proximal and distal region that has no FOXA2 binding ele-
ments were not speciﬁcally precipitated by the FOXA2. Taken
together, these results indicate that p21 transactivation induced
by TSA is regulated by FOXA1/2 binding at FRE2 in p21 promoter.
3.4. FOXA1/2 and SP1 are positive regulators for TSA-mediated p21
transcription
Since SP1 activates p21 expression after TSA treatment in p53-
negative human osteosarcoma MG63 cells [32], we next examinedthe signaling mechanism between FOXA1/2 and SP1 that regulates
p21 transactivation using luciferase analysis in H1299 cells. As
shown in Fig. 4A, TSA treatment increased luciferase activity of
p21-Luc by 6-fold (lane 2) compared to the untreated negative
control (lane 1). In contrast, TSA-induced p21 luciferase activity
was signiﬁcantly decreased in the FOXA1/2 knockdown (lane 4)
and the FOXA1/2 plus SP1 knockdown (lane 5) in H1299 cells com-
pared to those with the empty vector (lane 2). However, in only
SP1 knockdown H1299 cells, the reporter activity did not signiﬁ-
cantly decreased (lane 3). Although these results demonstrate that
transcriptional activity of SP1 was negligible, we found that our
reporter constructs including p21 promoter region do not have
strong six SP1 binding sites where 133  50 base pairs away
from transcriptional start site of p21 [32]. In this regard, p21-lucif-
erase reporter constructs are more useful to test FOXA1/2 medi-
ated transcriptional activation than testing of SP1 transcriptional
activity. To test the involvement of SP1 in p21 transcription, we
investigated p21 transcription level in H1299 cells that were
knock-downed of SP1 expression using its siRNA. As shown in
Fig. 4B, indeed, RT-PCR and Western blotting analysis using endog-
enous p21 promoter showed that the TSA-induced p21 mRNA and
protein expression was signiﬁcantly decreased in the knockdown
of SP1 (lane 3) and FOXA1/2 (lane 4) compared to the TSA-treated
empty vector transfectant (lane 2). Moreover, silencing of the
FOXA1/2 plus SP1 in H1299 cells signiﬁcantly blocked p21 tran-
scription in spite of TSA treatment (lane 5). Taken together, these
results indicate that TSA-dependent p21 transcription is induced
by FOXA1/2 and SP1 in H1299 cells.
4. Discussion
The expression of the cell cycle inhibitor p21 is increased in
response to various stimuli and stress signals through p53-depen-
dent and independent pathways. Several histone deacetylase
(HDAC) inhibitors activate p21 transcription in p53-independent
pathways either through enhancing histone acetylation or by
releasing HDAC repressors on the p21 promoter [4].
It has been previously reported that FOXA2 is constitutively
downregulated by mutation or hypermethylation of its promoter
in human lung carcinoma cells [18,19]. In this study, we found that
the HDAC inhibitor TSA induced FOXA1/2 expression in p53-null
H1299 cells. TSA has antitumor activity through the upregulation
of p21 expression, which results in cell cycle arrest at the G1 phase
and inhibition of cell proliferation in p53-deﬁcient cell lines [33–
36]. However, the FOXA1/2 regulatory mechanism for p21
expression in lung cancer cells has yet to be fully elucidated. We
investigated p21 transcriptional activation by the transcription
factor FOXA1/2, since the p21 promoter has FOXA1/2 binding
motifs based on search results using TFSEARCH software (Fig. 1).
Our results showed that the overexpression of FOXA1/2 increased
the expression of p21 mRNA and its proteins in p53-null H1299
cells. Transcriptional activation of p21 was regulated via direct
FOXA2 binding to the p21 promoter, in which FRE2 is responsible
for FOXA2-associated p21 transactivation. In addition, p21 expres-
sion was regulated by TSA-induced endogenous FOXA1/2 in H1299
cells, suggesting that FOXA1/2 regulate transcription of p21 in TSA-
treated p53-null H1299 cells together with SP1 which is known as
the p21 regulator (Fig. 4).
FOXA2 physically interacts with NKX2-1 in human lung adeno-
carcinoma cells, and the two proteins bind to adjacent sites on sev-
eral genes expressed in the lung to cooperatively activate
transcription [37,38]. Recently, Snyder et al. demonstrated that
NKX2-1 is required for the correct FOXA1/2 localization in lung
adenocarcinoma cells, suggesting that a global change in FOXA1/
2 binding is a critical step in the transition from a pulmonary to
a gastric differentiation state [39]. Thus, further studies are needed
Fig. 3. FOXA1/2 regulates p21 expression through binding to FRE2 of p21 promoter in TSA-treated H1299 cells. (A) H1299 cells were treated with TSA for the indicated time.
After harvesting, protein expression was examined by Western blotting using antibodies against FOXA1, FOXA2 and p21. Acetyl-a-tubulin was used as a positive control for
TSA treatment, and b-tubulin was used as a loading control. (B) H1299 cells transfected with siRNA against either FOXA1 or FOXA2, or a combination of both were treated
with ethanol or TSA for 12 h. After harvesting, the expression of p21 mRNA was analyzed by qRT-PCR, which was normalized to 18S rRNA (left panel). Protein levels were
veriﬁed by Western blotting using antibodies against p21, FOXA1 and FOXA2 (right panel). b-Tubulin was used as a loading control. Data represent the means ± S.E.M. from
three independent experiments. (⁄⁄⁄P < 000.1). (C) After ethanol or TSA treatment for 12 h, a ChIP assay was conducted on H1299 cells using antibody against FOXA1 or
FOXA2. Rabbit IgG was used as a negative control. The PDX1 promoter region was used as a positive control for FOXA2 binding. The precipitated fragments were examined by
PCR using p21 promoter-speciﬁc primers. Data represent the means ± S.E.M. from three independent experiments. (⁄⁄⁄P < 000.1). (D) Schematic diagram of primer pairs in the
distal region, FRE1, FRE2 and proximal region of the p21 promoter used in the ChIP assay (top panel). After H1299 cells were treated with TSA or ethanol, ChIP analysis was
conducted using anti-FOXA2 antibody, and the recruitment of FOXA2 to the p21 promoter region was normalized to the input (middle panel). Agarose gel electrophoresis of
the ampliﬁed PCR products was shown (bottom panel). Data represent the means ± S.E.M. from three independent experiments. (⁄⁄⁄P < 000.1).
Fig. 4. FOXA1/2 and SP1 are required for TSA-induced p21 transcription. (A) After H1299 cells were cotransfected with the p21 promoter-luc and pCMV-b-galactosidase
vector together with siRNA against either FOXA1/2 or SP1 or a combination of both followed by ethanol or TSA treatment for 12 h, the luciferase assay was performed. All data
were normalized to b-galactosidase activity. Data are expressed as the fold increase over relative luciferase units, which are normalized to control levels. Data are the
means ± S.E.M. from three independent experiments. (⁄⁄⁄P < 0.001). (B) After H1299 cells cotransfected with siRNA vectors against either FOXA1/2 or SP1, or a combination
of both were treated with ethanol or TSA for 12 h. The level of p21 mRNA was examined by qRT-PCR, and 18S rRNA was used as an endogenous control. The level of p21,
FOXA1/2, and SP1 protein expression was examined by Western blotting. b-Tubulin was used as a loading control.
J.-H. An et al. / FEBS Letters 588 (2014) 4065–4070 4069
4070 J.-H. An et al. / FEBS Letters 588 (2014) 4065–4070to assess the possible association between FOXA1/2 and NKX2-1 in
p53-null lung carcinoma cells, which may be critical in enhancing
FOXA1/2 binding to the p21 promoter.
In conclusion, our results demonstrate that FOXA1/2 is a crucial
transcription factor in the activation of p21 transcription via direct
binding to the p21 promoter in p53-null H1299 cells. In addition,
these results support the important role of inducing apoptotic cell
death in lung cancer through the p21 signaling pathway in a
p53-independent manner. Therefore, FOXA1/2-mediated cell death
pathway might be useful therapeutic target by increasing of its
transcriptional activity in lung carcinoma, which is usually unde-
tectable in early pathogenesis.
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